Ethan and Satoria presented at the Mid-Atlantic Pharmacology Society (MAPS) on the role of amylin in cocaine taking. Amylin is a satiety peptide that reduces food intake without producing GI distress or malaise-like side effects. It acts on amylin receptors (AMYRs) to modulate feeding and satiety, behaviors that rely on the brain’s reward pathway, so this study examined the effects of amylin on voluntary cocaine-taking and cocaine-seeking behavior. They found that amylin administered into the nucleus accumbens (NAc) shell reduced cocaine taking in a sex- and dose-dependent manner and reduced cocaine seeking in a dose-dependent manner. Importantly, intra-NAc amylin did not alter feeding or body weight in male or female rats during self-administration. They also showed that both AMYR components, CTR and RAMP1, are present and colocalize in cells of the NAc shell. Together, these findings support further development of amylin-based pharmacotherapies for treating cocaine use disorder (CUD).